Physician profile
Norberto Vazquez
NPI 1336114339
$5,240.02
in general payments reported to CMS, 2019-2025
44 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $136 · 2021: $681 · 2022: $698 · 2023: $1,147 · 2024: $811 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $658.15 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $642.58 | 2019-2025 | |
| Lilly USA, LLC | $452.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $355.18 | 2021-2023 | Ubrelvy, Qulipta |
| Exact Sciences Corporation | $310.97 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $226.77 | 2023-2025 | Gemtesa, Myfembree |
| Novo Nordisk INC | $194.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $187.39 | 2020-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $159.40 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $157.77 | 2019-2024 | Capvaxive |
| Glaxosmithkline, LLC. | $155.85 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $154.89 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $151.05 | 2023-2024 | Rexulti, Abilify Maintena |
| Radius Health, INC. | $123.97 | 2023-2025 | Tymlos |
| Abbott Laboratories | $116.29 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norberto Vazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.